Table 1.
Patient characteristics
| Variable | Median (IQR) or % (n, of 518) | |
|---|---|---|
| Age at diagnosis | 60 (50–68) | |
| Percent female | 46% (238) | |
| Race | ||
| White | 66% (340) | |
| East Asian | 14% (74) | |
| African American | 8.7% (45) | |
| Southeast Asian | 3.7% (19) | |
| Asian NOS | 3.7% (19) | |
| Other (includes American Indian, Pacific Islander) | 4.1% (21) | |
| Percent Hispanic | 9.1% (47) | |
| Survival time since diagnosis (months) | 28 (11–53) | |
| Primary diagnosis | ||
| Lung | 26% (137) | |
| Breast | 19% (97) | |
| Prostate | 9.7% (50) | |
| Renal cell | 5.8% (30) | |
| Colorectal | 5.8% (30) | |
| Hepatocellular | 3.8% (20) | |
| Head and Neck | 3.5% (18) | |
| Skin | 3.3% (17) | |
| Othera | 23% (119) | |
| Metastatic at diagnosis | 49% (254) | |
| Site of metastases | ||
| Brain | 47% (244) | |
| Lung | 55% (284) | |
| Liver | 40% (208) | |
| Bone only | 17% (90) | |
| BMI last course | 24(21–27) | |
| KPS last consult | 60 (50–80) | |
| KPS > 70 | 45% (231/511) | |
| Hospitalization within 3 months of RT consult | 58% (289/500) | |
| TEACHH scoreb | Median survival, months (IQR) | |
| 0–1 (Group A) | 6.2% (32/450) | 6 (2.8–11) |
| 2–4 (Group B) | 68% (352/450) | 2.2 (1.0–5.0) |
| 5–6 (Group C) | 13% (66/450) | 1.3 (0.5–2.3) |
| CHOW groupb | ||
| I | 18% (92/510) | 4.7 (2–11) |
| II | 44% (227/510) | 2.5 (1.0–5.6) |
| III | 37% (191/510) | 1.6 (0.7–2.7) |
| Hospice involved | ||
| Yes | 47% (245) | |
| No | 28% (147) | |
| Unknown | 24% (126) | |
| Place of death | ||
| Inpatient, acute care | 23% (120) | |
| Home | 29% (151) | |
| Inpatient hospice, non-acute care | 10% (52) | |
| SNF (not hospice) | 1.5% (8) | |
| Unknown | 36% (187) | |
aIncludes primary cancer of the liver, bile ducts, esophagus, ovary, pancreas, meninges, endometrium, anus, lymph nodes, CNS, and pleura
bSome patients had incomplete information and thus TEACHH or Chow groups could not be calculated (denominators 450 and 510 respectively). Performance status at RT consult was the most commonly missing information, but also hospitalizations within 3 months of RT consult and number of prior palliative chemotherapy courses